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Objective. To investigate the relation between sever­
ity of complaints, laboratory data and psychological 
parameters in patients with chronic fatigue syndrome 
(CFS).
Subjects. Eighty-eight patients with CFS and 77 
healthy controls matched for age, sex and geo­
graphical area.
Methods. Patients and controls visited our outpatient 
clinic for a detailed medical history, physical exam ­
ination and psychological tests: Checklist Individual 
Strength (CIS). Beck Depression Inventory (BDI) and 
Sickness Impact Profile (SIP). Venous blood was 
drawn for a complete blood cell count, serum 
chemistry panel. C-reactive protein and serological 
tests on a panel of infectious agents.
Results. All patients fulfilled the criteria for CFS as
described by Sharpe et til. (/ R Soc Med 1991: 84:
1 18-21). only 18 patients (20.5%) fulfilled the CDC 
criteria. The outcome of serum chemistry tests and 
haematological tests were within the normal range. 
No significant differences were found in the outcome 
of serological tests. Compared to controls, significant 
differences were found in the results on the CIS. the 
BDI. and the SIP. These results varied with the 
num ber of complaints (CDC criteria). When the 
number of complaints was included as the covariate 
in the analysis, there were no significant differences 
on fatigue severity, depression, and functional im­
pairment between patients who fulfilled the CDC 
criteria and patients who did not.
Conclusion. It is concluded that the psychological 
parameters of fatigue severity, depression and func­
tional impairment are related to the clinical severity 
of the illness. Because the extensive panel of lab­
oratory tests applied in this study did not discriminate 
between patients and controls, it was not possible to 
investigate a possible relation between the outcomes 
of psychological and laboratory testing.
Keywords: chronic fatigue syndrome. CFS, postviral 
fatigue, PVFS.
Introduction
Chronic fatigue syndrome (CFS) is characterized by 
severe disabling fatigue of definite onset (not lifelong), 
lasting for more than  1 year, and for which no 
explanation can be found. The fatigue is often 
accompanied by a variety of non-specific symptoms 
and signs. The aetiology of CFS is not known. For 
research purposes, the Centres for Disease Control 
described a working case definition, which repre­
sented a consensus opinion rather than validated 
criteria [ 1 ]. Similar but less stringent case definitions 
were subsequently proposed in the IJK [2| and in 
Australia [3|. In these case definitions, the fatigue 
has to be disabling, of definite onset, and lasting for 
at least 6  m onths; other symptoms, such as myalgia 
and neuropsychological problems, may be present 
but are not required.
A num ber of somatic and psychological hypotheses 
have been proposed as possible explanations for the
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cause of CFS [4. 5]. One of these hypotheses is that a 
persistent viral infection leads to continuous immune 
activation with production of pro-inflammatory cyto­
kines, which could explain a num ber of symptoms 
[6 ,7 ,8 ] .  According to another hypothesis the pri­
mary defect is an immune dysfunction, tha t includes 
inadequate killing of virus-infected cells, thereby 
resulting in persistent infection [9 ,1 0 .1 1 ] .  Some 
researchers have proposed tha t CFS is an atypical 
manifestation of a depression 1 1 2 . 1 31. whilst others 
think that the perpetuation of the complaints is the 
result of prolonged physical inactivity (14]. Recently, 
impaired activation of the hypothalam ic-pitu itary- 
adrenal axis has been found in patients with CFS 
[15]. Altered reactivity of the hypothalam ic- 
pituitary-adrenal axis has also been described for 
patients with the primary fibromyalgia syndrome, 
which is thought to be closely related to CFS [16].
Abnormalities observed in serological and im m u­
nological studies on patients with CFS are diverse, 
sometimes conflicting, and often minimal. In some 
studies, patients were selected on postviral fatigue, 
severe myalgia and muscle weakness [17-19], 
whereas in other studies, CFS patients were selected 
on increased antibody titres to EBV [11,20]. As a 
consequence, these data cannot be extrapolated to 
CFS patients in general. The impact of the ab­
normalities in laboratory studies is not clear, because 
usually a correlation with clinical severity of the 
illness is not made.
In the present study, laboratory data of patients 
with severe disabling fatigue lasting for more than  1 
year have been compared with those of a well 
matched control group. Our leading question was to 
investigate w hether there would be a relation be­
tween severity of the complaints, laboratory data and 
the psychological parameters fatigue severity, de­
pression and functional impairment. Furthermore, 
we investigated w hether patients who fulfill the CDC 
criteria differ from patients who do not, clinically, in 
laboratory tests or in psychological tests. The study 




One-hundred patients were randomly chosen from a 
database of 298 patients with CFS. The latter patient
group, which was self-referred, was described in 
detail by Vercoulen et al. [21]. In brief, all patients 
experienced severe disabling fatigue, of definite onset, 
lasting for more than  1 year; other symptoms may be 
present but are not required. Patients with estab­
lished medical conditions known to produce chronic 
fatigue, and patients with a diagnosis of schizo­
phrenia. bipolar disorder, psychotic depression, sub­
stance use disorder, eating disorder, or proven 
organic brain disease were excluded. The selected 
patients were invited to visit our outpatient clinic for 
a detailed medical history as well as a physical 
examination. All patients gave their informed con­
sent.
Blood samples were taken for complete blood cell 
counts, a serum chemistry panel, which included 
sodium, potassium, calcium, bicarbonate, glucose, 
creatinine, creatinine phosphokinase, liver function 
tests (lactic dehydrogenase, alkaline phosphatase, 
alanine aminotransferase, gamma-glutamyl transfer­
ase), and red blood cell magnesium (RBC-Mg). Three 
patients dropped out during these investigations.
In nine patients, medical history and physical 
examination revealed other diagnoses that might 
contribute to their complaints (chronic pancreatitis, 
diabetes mellitus, severe chronic obstructive pul­
monary disease (COPD), cardiac arrhythm ia, a n ­
orexia, colon carcinoma, cocaine abuse, manic de­
pressive disorder, paranoia). These patients were 
excluded from the analyses. The remaining 8 8  
patients were asked to visit our clinic again after 3 
m onths and to bring a healthy, non-fatigued control 
subject with them, matched for gender, age and 
geographical area. The use of healthy neighbourhood 
controls is necessary to control for recent local 
epidemics. Seventy-seven patients were able to find 
such a control. None of the controls were receiving 
medical treatment, and they all stated that they were 
not feeling fatigued.
Clinical examination
Questionnaire. Patients and controls were asked to 
complete a questionnaire. With this questionnaire, 
information was obtained on age. sex. marital status, 
education, occupation, duration of the symptoms, 
medication and treatment. Information on the num ­
ber and presence of the complaints was obtained in 
two ways. One way was to ask both the patients and 
the controls to write down their complaints with a
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maximum  of 1 6  (spontaneously reported). The other 
way was to ask them w hether they had a specific 
complaint or not (standardized questionnaire), and 
how often it was present using a 4-point scale: 1 =  
never; 2 =  several times per m onth ; 3 =  several 
times per week; 4 =  every day. Because a score 
below 3 did not discriminate between patients and 
controls, a specific complaint was scored as being 
present when the score was 3 or 4 .
Physical examination. All patients had an extensive 
physical examination with special attention for 
swollen lymph nodes, pharyngitis, muscle atrophy, 
muscle strength, and tendon reflexes. Unless indi­
cated by medical history, a physical examination of 
controls was not done.
Laboratory tests
Blood samples were taken for a complete blood cell 
count, differential count, C-reactive protein and 
serological tests on a panel of infectious agents. 
Antibodies to viral capsid antigen and to early 
antigen of Epstein-Barr virus were detected by 
indirect immunofluorescence on HH514 cells. These 
cells are a subclone of P3HR1 and were kindly 
provided by Dr G. Miller (Yale University School of 
Medicine. New Haven, CT, USA). Raji cells were used 
for the detection of antibodies against Epstein-Barr 
virus nuclear antigen. HSB-2/HHV-6(;s cells (ob­
tained from the AIDS Research and Reference Re­
agents Program of the NIH) were used for the 
detection of immunoglobulin G (IgG) and IgM against 
hum an  herpesvirus type 6 . Before IgM was tested, 
serum samples were incubated with GullSORB (Gull 
Laboratories. UT. USA), to remove IgG and rheu­
matoid factor. ELISAs for antibodies against cyto­
megalovirus (CMV) and Toxoplasma gondii were 
performed as described by van Loon et al. [22]. 
Toxoplasma IgG was expressed in international units 
(III) and CMV-lgG antibodies in arbitrary units (AU) 
using a standard curve of reference serum samples. 
Antibody capture ELISAs were used for the detection 
of IgM and IgA antibodies. For the detection of 
enteroviral IgG, IgM and IgA. antibodv-capture 
ELISAs were used as recently described |2 3|. For all 
ELISAs except Toxoplasma, IgG, and CMV-lgG, a ratio 
was computed as follows: the extinction of each 
serum was divided bv the extinction of a cut-off’
serum. When the ratio was > 1 . 2  a serum was 
considered positive, when the ratio was ^  1 a serum 
was considered negative, when the ratio was in 
between, this was considered indeterminate.
Psychological tests
Different aspects of fatigue, depression, and functional 
impairment were measured as described before [ 2 1  ]. 
The following tests were used.
Fatigue questionnaire. The Checklist Individual 
Strength (CIS) is a reliable and validated ques­
tionnaire designed to measure four aspects of fatigue, 
namely subjective experience of fatigue (eight items), 
concentration (five items), motivation (four items), 
and physical activity (three items) [2 11. Each subscale 
has a maximum score of 7. High scores indicate a 
high level of fatigue, a high level of concentration 
problems, low motivation, and a low level of physical 
activity.
Depression. Depression was assessed by the Beck 
Depression Inventory (BDI) [24]. A score of 16 or 
more is indicative of a clinical depression.
Functional impairment. The effect of the complaints on 
daily functioning was assessed by the Dutch version 
of the Sickness Impact Profile (SIP), which is psycho- 
metrically similar to the English version [25.26). 
Because of the virtual absence of sickness in the 
healthy control group, we used normative data, 
which are available for patients who reported to have 
complaints of minor severity or no physical com­
plaints at all (n = 4 5 0 ; mean age, 47  years), and of 
patients who reported to have moderate to severe 
physical complaints (n = 144; mean age, 49 years)
[26].
Statistical analysis
Differences between patients and controls were tested 
using Student’s i-test for normal distributed variables. 
Non-parametric tests such as M ann-W hitney’s Li- 
test and chi-squared tests were used when appro­
priate. Testing differences between three groups or 
more was performed by analysis of variance (a n o v a ). 
When appropriate, covariates were included in
A N O V A .
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Results
Clinical data
Questionnaire. T h e  m e a n  ag e  of th e  88  p a t ie n ts  w a s  
4 0  (sn 1 0 .7 ;  r a n g e  2 0 - 6 6 )  y ea rs .  T h e  m a le : f e m a le  
ra t io  w a s  1 : 3 (2 3 m a le s  a n d  6 5  fem ales). S ix ty -seven  
per c e n t  w e re  m a r r ie d  o r  c o h a b ite d .  2 6 %  w e re  
s ing le , 2 %  w e re  d ivo rced , a n d  5%  w id o w e d . S ev en ty -  
sev en  p a t ie n ts  w e re  ab le  to  Hnd a h e a l th y  c o n tro l  
m a tc h e d  for age  (m e a n  ag e  41 y e a r s ;  sn 1 1 .3 ) ,  sex 
(m a le : f e m a le  ra t io ,  1 :3 ) ,  a n d  g e o g ra p h ic a l  a re a .  
T h e re  w e re  n o  d ifferences of so c io e c o n o m ic  a n d  
m a r i ta l  s t a tu s  b e tw e e n  p a t ie n ts  a n d  c o n tro ls .  T h ir ty -  
o n e  p a t ie n ts  (3 5 % )  w e re  on  sick leave, a n d  a n  
a d d it io n a l  30 (3 4 % )  w e re  n o t  w o rk in g  a t  th e  t im e  of 
o u r  s tu d y . O nly  2 5 p a t ie n ts  (2 9 % )  re p o r te d  to  be a t  
w o rk , c o m p a re d  to  54  (7 1 % )  of th e  c o n tro ls  (chi- 
s q u a re d  test. P  =  0 .0 0  3). S ix ty -seven  per c e n t  o f th e  
p a t ie n ts  w o rk ed  before th e  o n se t  o f th e  c o m p la in ts .  
Of th e  p a t ie n ts  still w o rk in g .  12 (4 8 % )  w o rk e d  p a r t-  
t im e  as a re s u l t  o f th e i r  c o m p la in ts .
All p a t ie n ts  h a d  v isited  o n e  o r  m o re  spec ia lis ts  for 
th e i r  c o m p la in ts  (p re d o m in a n t ly  in te rn is t ,  n e u r o l ­
ogist. p sycho log is t,  p sy c h ia tr is t ,  rh e u m a to lo g is t ) .  
S ixty-five per cen t of th e  p a t ie n ts  w e re  ta k in g  
m e d ic a t io n  (m a in ly  an a lg es ic s ,  v i ta m in s ,  a n d  h o m e o -
Table 1 Complaints of 8<S patients with chronic fatigue
Complaint
Num ber (%) 
standardized*
Num ber (%)
spo n tan eo us!
Fatigue 88 ( 1 0 0 ) 8 8 ( 1 0 0 )
Myalgia 66 (75) 46  (55)
Castro-intestinal complaints 59 (67) 42 (48)
Concentration problems 57 (65) 30 (34)
Allergies 57 (65)
Muscle weakness 53 (60) 24  (29)
Sleeping problems 42 (48) 24  (29)
Memory problems 42 (48) 1 7 ( 1 9 )
Arthralgia 39 (44) 28 (32)
Headache 34 (39) 41 (47)
Irritability 29 (33) 12 (14)
Dizziness 27  (31) 21 (24)
Sore throat 19 (22) 11 (13)
Polyuria 15 (17)
Depressive feelings 14 (16) 10  ( 1 1 )
Recurrent infections 1 4 ( 1 6 ) 13 (15)
Blurred vision 12 (14)
Lym phadenopathy 12 (14) 4 (5)
Slightly elevated body 7 (8 ) 9 ( 1 1 )
temperature
* Obtained by standardized questionnaire, 
t  Spontaneously reported complaints.
Table 2 Results of serological tests




(n = 8 8 )
Controls 
(n = 77)
Treponema pallidum MHT negative negative
Brucella abortus agglutination <  10 <  10
Brucella abortus CFT <  4 <  4
EB viral capsid antigen IgG 39.5 (32) 38 .0  (32)
EB viral capsid antigen IgM <  10 <  1 0
EB viral capsid antigen IgA <  8 <  8
EB early antigen IgG 10.3 (8 ) 7.4 (8 )
EB early antigen IgA <  8 <  8
EB nuclear  antigen 32.1 (16) 40 .2  (32)
Herpesvirus-6 IgG 15.5 (10) 16.8 ( 1 0 )
Herpesvirus-6 IgM <  10 <  10
Borrelia IgG 5 positivei* 4 positive*
Borrelia IgM <  8 <  8
Enterovirus CFT 36.3 (32) 35.7 (32)
Enterovirus IgG (ratio) 0 .43 0.51
Enterovirus IgM (ratio) 0.68 0.61
Enterovirus IgA (ratio) 0 .25 0 .37
Toxoplasma IgG (III) 175.6 1 30.8
Toxoplasma IgM (ratio) 1 . 1 0 .9 7
Cytomegalovirus IgG (All) 2 3.4 34.7
Cytomegalovirus IgM (ratio) 0.71 0.61
Cytomegalovirus IgA (ratio) 1 .0 1 .0
* Number of positives.
P. not significant for all serological tests.
AU. arbitrary units;  CFT, complement fixation test; EB, 
Epste in-Barr ; III, in ternational units;  MHT. micro 
haem agglu t ina t ion  test.
p a th ic  d ru g s )  v e rsu s  1 6 %  of c o n tro ls  (m a in ly  in ­
c id en ta l  u se  of an a lg es ic s ) .  S ix ty-six  per c e n t  of th e  
p a t ie n ts  re p o r te d  a n  a c u te  o n se t  of sy m p to m s  a fte r  
a n  in fec tiou s  illness. T h is  is d ifferen t from  th e  s tu d ie s  
in th e  UK o n  p o s t-v ira l  fa tig u e  s y n d ro m e , in w h ic h  
a t t r ib u t io n  to  a n  a c u te  v ira l illness is a c r i te r io n , b u t  
s im ila r  to  s tu d ie s  fro m  th e  USA a n d  A u s tra l ia .  In
2 3%  of th e  p a t ie n ts  th e  o n se t  of s y m p to m s  w a s  
g ra d u a l .  1 1 % of th e  p a t ie n ts  did n o t  k n o w  h o w  th e  
s y m p to m s  h a d  b e g u n .  T h e  a v e ra g e  d u r a t io n  of 
s y m p to m s  w a s  11 y ea rs ,  (m e d ia n  7 y e a r s ;  r a n g e
2 - 4 5  y e a rs ) .  C o m p la in ts  t h a t  w e re  re p e a te d ly  p re se n t  
(m o re  t h a n  o n c e  a w eek) d u r in g  th e  p as t  3 m o n th s  
a re  p re se n te d  in T ab le  1. It sh o u ld  be n o te d  t h a t  th e  
n u m b e r  of c o m p la in ts  w a s  h ig h e r  w h e n  specifically  
asked  for. c o m p a re d  to  w h e n  s p o n ta n e o u s ly  rep o rted . 
W h e n  specifically  asked  for. th e  m e d ia n  n u m b e r  of 
c o m p la in ts  for p a t ie n ts  w a s  e ig h t  ( ra n g e ,  th re e  to  
s ix teen ), for c o n tro ls  zero  ( ra n g e  zero  to  four). Based 
on  th e  s ta n d a rd iz e d  q u e s t io n n a i re .  18 p a t ie n ts
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Table 3 Mean CIS scores of 88 patients and 77 controls
Mean value ( ± so )
Subscales Patients Controls P-va lue
Subjective fatigue 5.8 (1.1) 1.8 (0.9) <  0.001
Concentration 4 .4  (1.6) 2.3 (1.2) <  0.001
Motivation 3.2 (1.7) 1.9 (1.0) <  0 .0 0 1
Activity 4.3 (1.7) 1.9 (1.2) <  0.001
(20.5%) fulfilled the CDC criteria. For all patients, the 
median num ber of minor CDC criteria was six. All 
patients fulfilled the criteria for CFS as described by 
Sharpe et al. [2].
Physical examination. Physical examination revealed 
no abnormalities, especially no swollen lymph nodes, 
no pharyngitis, no muscle atrophy and normal 
tendon reflexes.
Laboratory results
The outcome of laboratory tests was similar for 
patients and controls. Serum chemistry tests and 
haematological tests were within the normal range 
(data not shown). Red blood cell magnesium was 
143.7 ng Mg per gram RBC (s d  15.8) (normal 
152 |ig Mg per gram RBC; s d  30.0).
Results of serological tests are presented in Table 
2. Again no significant differences were found 
between patients and controls. C-reactive protein.
which is usually high in case of an infection, was low 
( <  10 mg L 1) in both patients and controls.
Results of psychological tests
Subjective feeling of fatigue. Scores of the fatigue 
questionnaire (CIS) are presented in Table 3. Patients 
were significantly more fatigued than  controls as 
measured by the subscale subjective fatigue. Patients 
with CFS experienced significantly more concen­
tration problems, had lower motivation, and showed 
less physical activity than  healthy controls.
Depression. Patients had significantly higher scores 
on the Beck Depression Inventory than  controls. By 
using a score of 16 as the cut-off point. 18.3% of 
patients could be considered depressed versus 1.3% 
of controls (P <  0 .0 0 1 ).
Functional impairment. Data on the inventory for 
functional impairment (SIP) are depicted in Fig. 1. 
Patients with CFS scored significantly higher when 
compared to reference group 1 (no physical com­
plaints or physical complaints of minor severity) 
(P <  0.001 for all subscales). When patients with 
CFS were compared to reference group 2 (patients 
with moderate to severe physical complaints), 
patients with CFS scored significantly higher on alert­
ness behaviour (P <  0.001). and work (P <  0.001). 
There were no significant differences on the other 
subscales.
35
Fig. 1 SIP scores of 88 CFS 
patients ( ■ )  compared to 
reference group 1 (0 ) (physical 
complaints of minor severity or no 
physical complaints at  all) and 
reference group 2 (D )  (moderate 
to severe physical complaints).
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Fulfilment of CDC criteria
There were no differences in fatigue severity (CIS 
subjective fatigue) between patients who fulfilled the 
CDC criteria (CDC-CFS patients) and patients who did 
not (non CDC-CFS patients). No differences on any of 
the laboratory tests could be found when CDC-CFS 
patients were compared with non-CDC-CFS patients. 
W hen CDC-CFS patients were compared with non- 
CDC-CFS patients, there was a significant difference 
in CIS concentration (P <  0.05), CIS activity (P <
0.01 ). SIP sleep and rest (P <  0.05), SIP ambulation 
(P <  0.05), SIP alertness behaviour (P <  0.05) and 
SIP recreation and pastimes ( P c O .O l ) .  which 
means that patients who have more complaints are 
significantly more impaired in daily functioning. 
When the num ber of complaints was included as 
covariate in the analysis, only a significant difference 
in recreation and pastimes remained (P <  0.05).
Discussion
In this paper, clinical, laboratory and psychological 
findings of a cohort of patients with CFS are compared 
to those of a well matched control group. Most 
studies on CFS described in the literature have 
secondary or tertiary referred patients. To avoid this 
selection bias, we chose to include self-referred 
patients, which by nature  could be expected to be 
more representative of the general problem. That 
these patients were severely fatigued and were 
considerably impaired by their complaints is clear 
from our data on the fatigue questionnaire (CIS) and 
inventory for functional impairment (SIP). There 
was a remarkable discrepancy between sponta­
neously reported complaints and those acquired by 
a standardized questionnaire as is shown in Table 1. 
Using the standardized questionnaire, in which it is 
specifically asked w hether a complaint is present, 
complaints were more frequently reported. This 
implies that the num ber of criteria that are scored 
depends on how data are collected. In this study, the 
num ber of CDC symptom criteria was based on the 
data from the standardized questionnaire. Although 
only 18 patients of our study population (20.5%) 
fulfilled the CDC criteria, there were no differences in 
fatigue severity (CIS subjective fatigue) between 
patients who fulfilled the CDC criteria and patients 
who did not. W hen the num ber of complaints was 
included as a covariate in the analysis, there were
also no significant differences on depression and 
functional impairment. As there was no difference in 
any of the laboratory parameters, the sole effect of 
applying the CDC symptom criteria on our study 
group is separating patients with few symptoms from 
patients with m any symptoms. For the group as a 
whole, the median num ber of minor CDC criteria was 
six. It should be noted that the minor criteria that 
are obtained by physical examination all focus on 
inflammation (or even infection), whilst an  infectious 
aetiology forms only one of the possible explanations 
for CFS. Although 6 6 % of the patients reported an 
acute onset of their complaints after an infectious 
illness, we did not find abnormalities on physical 
examination, and symptom criteria tha t focus on 
inflammation, such as sore throat, lymph-adeno- 
pathy, and mild fever, scored relatively low (22. 14. 
and 8 %. respectively). This might be related to the 
long duration of symptoms. Many patients reported 
that such symptoms had been present during the first 
few m onths of their illness. However, this was not 
documented by a physician and may just reflect 
attribution to a ‘v ira l’ cause.
With regard to laboratory findings, low m ag­
nesium concentrations in red blood cells (RBC-Mg) 
has been described by some researchers [27]. In our 
study. RBC-Mg was normal in CFS patients, and this 
is in accordance with the findings of others [28. 29].
We could not detect differences on the serological 
parameters when patients were compared with 
matched controls. By the testing of paired sera, 
evidence was found for a recent Toxoplasma gondii 
infection in one patient, but there was no relation to 
the duration of the fatigue. Despite the fact tha t no 
differences were found between patients and controls 
in laboratory tests, we did find significant differences 
on the fatigue scale, the inventory for depression and 
functional impairment, when CFS patients were 
compared to controls. However, this does not imply 
that CFS is a psychiatric disease. Although depression 
scores were higher amongst patients than  amongst 
controls, only 1 8 % of the patients could be considered 
depressed, whereas 59% of the patients did not have 
depressive feelings at all.
Results on the inventory for functional impairment 
(SIP) indicate that CFS patients are considerably 
impaired by their complaints. Compared to patients 
with moderate to severe physical complaints (re­
ference group 2). CFS patients stopped working more 
often (SIP work; P <  0.001), and are significantly
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more impaired by neuropsychological problems (ex­
pressed by SIP alertness behaviour; P <  0.001). The 
m easurem ent of these neuropsychological problems 
deserves more attention and is a subject for future 
research. We need to get a better idea of exactly how 
CFS patients and non-symptomatic, normal subjects 
differ in terms of attention and concentration, cog­
nitive functioning, memory, various dimensions of 
mood and emotional functioning, in addition to 
quality of everyday-life functioning. Neuropsycho­
logical problems may also be a symptom of dysregu- 
lation of the hypothalam ic-hypopituitary-adrenal 
axis, which has been recently described by Demitrack
et a l  [15].
As the laboratory parameters tha t were used in 
this study were within the normal range, they could 
not be correlated with the severity of the illness, or to 
the CDC criteria. Therefore, it was not possible to 
investigate a relation between the outcome of psycho­
logical and laboratory testing. The fatigue ques­
tionnaire (CIS), the depression inventory (BDI), and 
the inventory for functional impairment (SIP) corre­
lated with clinical severity of the complaints and are 
valuable tools in the assessment of patients with CFS. 
Serological tests, however, are not helpful in assess­
ing the presence or absence of CFS, because these 
tests did not discriminate between patients and 
controls.
Acknowledgements
This work was in part supported by grant no. 28- 
1969 from the Praeventiefonds, and by a grant from 
the University Hospital Nijmegen.
We thank  L. Veenstra, B. Kohler. Dr J. Willems 
and B. R. Cockx for excellent help in this study.
References
1 Holmes GP, Kaplan IE. Gantz NM. Komaroff AL. Schonberger 
LB. Straus SE cl al. Chronic fatigue syndrome: a working case 
definition. Ann Intern Med 1 9 8 8 :  108:  387-9 .
2 Sharpe MC. Archard LC. Banatvala JE. Borysiewicz LK. Clare 
AW. David A et ul. A report-chronic fatigue syndrome: 
guidelines for research. / R Soc Med 1991;  8 4 :  1 1 8 -2 1 .
3 Lloyd AR. Hickie I. Boughton CR. Spencer 0 ,  Wakefield D. 
Prevalence of chronic fatigue syndrome in an Australian 
population. Med ] Aust 1990:  1 53: 5 2 2 -8 .
4 Shafran SI). The chronic fatigue syndrome. Am  ] Med 1991 : 
9 0 :  7 3 0 - 3 9 .
5 Klonoff DC. Chronic fatigue syndrome. Clin Infect Dis 1992:  
15:  8 1 2 - 2 3 .
6 Komaroff AL. Chronic fatigue syndromes: relationship to 
chronic viral infections. J Virol Methods 1988:  2 1 :  3-10 .
7 Jones JE. Serologic and  immunologic responses in chronic 
fatigue syndrome with emphasis  on the Epstein-Barr virus. 
Rev Infect Dis 1991 ;  13 (Suppl. 1): s 2 6 -3 1 .
8 Yousef GE, Bell EJ, M ann GF, M urugesan V. Smith DG. 
McCartney RA. chronic enterovirus infection in patients with 
postviral fatigue syndrome. Lancet 1988 :  i: 1 4 6 -5 0 .
9 Gin W. Christiansen FT. Peter JB. Im m une  function and the 
chronic fatigue syndrome. Aled / Aust 1989:  1 5 1 : 1  17 -18 .
10 Lloyd AR. Wakefield I). Boughton CR. Dwyer JM. Im m u n o ­
logical abnormalities in the chronic fatigue syndrome. Med ƒ 
Aust 1989:  1 51 :  122-4 .
1 1 Klimas NG. Salvato FR. Morgan R. Fletcher MA. Im m uno­
logic abnormalities in chronic fatigue syndrome. / Clin 
Microbiol 1990:  2 8 :  1 4 0 3 -1 0 .
12 Abbey SE. Garfinkel PE. Chronic fatigue syndrome and 
depression: cause, effect, or covariate. Rev Infect Dis 1 9 9 1 ;  13 
(Suppl. 1): s 7 3—8 3.
1 3 Ray C. Interpreting the role of depression in chronic fatigue 
syndrome. In: Jenkins R. Mowbray R. eds. Post-viral Fatigue 
Syndrome. Chichester: John Wiley & Sons. 1991 : 9 3-1 1 3.
14 Butler S. Chalder T. Ron M. Wessely S. Cognitive behaviour 
therapy in chronic fatigue syndrome. J Neurol Neurosurg 
Psychiatry 1991 ;  54 :  1 5 5 3 -8 .
1 5 Demitrack MA. Dale JK. Straus SE. Laue L. Listwak SJ. Kruesi 
MJP et al. Evidence for impaired activation of the hypo- 
tha lam ic-hypopitu i ta ry-adrena l  axis in patients with chronic 
fatigue syndrome. / Clin Endorinol Metab 1 99 1 ; 73 :  1 2 2 4 -3 4 .
1 6 Griep EN. Boersma JW. de Koet ER. Altered reactivity of the
hypotha lam ic-p i tu i ta ry -adrena l  axis in the primary fibro­
myalgia syndrome. J Rheumatol 1993;  2 0 :  4 6 9 - 7 4 .
17 C unn ingham  L. Bowles NE. Archard LC. Persistent virus 
infection of muscle in postviral fatigue syndrome. Brit Med 
Bull 1991 ;  4 7 :  8 5 2 - 7 1 .
18 Archard LC. Bowles NE. Behan PO. Bell EJ. Doyle D. Postviral 
fatigue syndrome: persistence of enterovirus RNA in muscle 
and elevated creatine kinase. / R. Soc Med 1988 ;  81 :  326-9 .
19 Gow JW. Behan WMH, Clements GB. Woodall C. Riding M. 
Behan PO. Enteroviral RNA sequences detected by polymerase 
chain  reaction in muscle of patients with postviral fatigue 
syndrome. Br Med / 1991;  3 02 :  6 9 2 -6 .
20  Caligiuri M. Murray C. Buchwald D. Levine H. Cheney P. 
Peterson D. Komaroff AL. Ritz J. Phenotypic and  functional 
deficiency of natural  killer cells in patients with chronic 
fatigue syndrome, J Immunol 1987 ;  1 39: 3306-1  3.
21 Vercoulen JHMM, Swanink CMA. Fennis JFM. Galanía JMD, 
van der Meer JWM. Bleijenberg G. Dimensional assessment of 
chronic fatigue syndrome. / Psychosom Res 1994 :  38: 38 3-92.
22 van Loon AM. van der Logt JThM. van der Veen J. Enzyme- 
linked im m unosorbent  assay for m easurem ent  of antibody 
against cytomegalovirus and rubella virus in a single serum 
dilution. I Clin Pathol 1 9 8 1 ;  34 :  6 6 5 -9 .
2 3 Swanink CMA. Veenstra L. Poort YAGM, Kaan JA. Galama
JMD. A Coxsackievirus B1 based antibody-capture enzyme- 
linked immunosorbent  assay for the detection of im m uno­
globulin G (IgG). IgM and IgA with broad specificity for 
enteroviruses. J Clin Microbiol 1993;  31: 3 2 4 0 —46.
24 Beck AT. Ward CH. Mendelson M. Mock JE. Erbaugh JK. An 
inventory for measuring  depression. Arch Gen Psychiatry 
1 9 6 1 ;  4 :  5 6 1 -7 1 .
25 Bergner M. Bobbit RA. Carter WB. Gilson BS. The Sickness 
Impact Profile: development and final revision of a health 
status measure. Medical Care 1981 ;  19: 7 8 7 -8 0 5 .
© 1995 Blackwell Science Ltd Journal of Internal Medicine 2 37: 4 9 9 - 5 0 6
5 0 6  C. M. A. S W A N I N K  et al
26  Jacobs HM. Luttik A. Touw-Otten FWMM. and Melker RA. De 
‘sickness impact profile’: resultaten van een validering- 
sonderzoek van de Nederlandse versie. Ned Tijdschr Genceskd 
1 9 9 0 :  1 34: 1 9 5 0 -5 4 .
2 7  Cox IM. Campbell MJ, Dowson D. Red blood cell magnesium 
and  chronic fatigue syndrome. Lancet 1991 : 3 37: 7 5 7 - 6 0 .
28 Gantz NM. Magnesium and chronic  fatigue. Lancet 1991 :
3 38: 66 .
29 Deulofeu R. Gascon |. Gimenez N. Corachan M. Magnesium 
and chronic fatigue syndrome. Lancet 1991 ; 3 38: 641 .
Received 22 September 1 9 9 4 :  accepted 1 December 1994.
Correspondence: C. M. A. Sw anink  MD. University Hospital 
Nijmegen. Department of Medical Microbiology. PO Box 9 10 1 .  
6 5 0 0  HB Nijmegen. The Netherlands.
© 1995 Blackwell Science Ltd Journal of Internal Medicine 2 37: 4 9 9 - 5 0 6
